Literature DB >> 12634250

Clodronate induced uveitis.

P Fietta, P Manganelli, L Lodigiani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12634250      PMCID： PMC1754489          DOI： 10.1136/ard.62.4.378

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  17 in total

Review 1.  Ocular adverse effects associated with systemic medications : recognition and management.

Authors:  Ricardo M Santaella; Frederick W Fraunfelder
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 2.  Screening, diagnosis and treatment of osteoporosis: a brief review.

Authors:  Roberto Bernabei; Anna Maria Martone; Elena Ortolani; Francesco Landi; Emanuele Marzetti
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

3.  Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial.

Authors:  D V Patel; M Bolland; Z Nisa; F Al-Abuwsi; M Singh; A Horne; I R Reid; C N J McGhee
Journal:  Osteoporos Int       Date:  2014-09-04       Impact factor: 4.507

4.  Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.

Authors:  Beate Aurich-Barrera; Lynda Wilton; Scott Harris; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

6.  Salt-sensitive increase in macrophages in the kidneys of Dahl SS rats.

Authors:  Daniel J Fehrenbach; Justine M Abais-Battad; John Henry Dasinger; Hayley Lund; David L Mattson
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-19

Review 7.  Risedronate-associated scleritis: a case report and review of the literature.

Authors:  Iman Hemmati; John Wade; John Kelsall
Journal:  Clin Rheumatol       Date:  2012-08-05       Impact factor: 2.980

8.  Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.

Authors:  H Tannenbaum; F Berenbaum; J-Y Reginster; J Zacher; J Robinson; G Poor; H Bliddal; D Uebelhart; S Adami; F Navarro; A Lee; A Moore; A Gimona
Journal:  Ann Rheum Dis       Date:  2004-02-27       Impact factor: 19.103

Review 9.  Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

Authors:  Raja S Bobba; Karen Beattie; Bill Parkinson; Dinesh Kumbhare; Jonathan D Adachi
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

10.  Drug-induced uveitis.

Authors:  Nikolas Js London; Sunir J Garg; Ramana S Moorthy; Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.